Welcome to AiCuris: The Powerhouse for Anti-infectives    

 

“Committed to making the difference”

AiCuris is a pharmaceutical company focused on the discovery, research and development of novel, resistance-breaking antiviral and antibacterial agents for the treatment of severe and potentially life-threatening infectious diseases.

Founded in 2006 as a spin-out from Bayer's virology and bacteriology research department, AiCuris is now an established “powerhouse for anti-infectives” and is one of the few biotech companies world-wide to have successfully brought a drug to market, and therefore to patients (Prevymis® 2017/18).

Today AiCuris has an innovative pipeline of anti-infective agents and a team of internationally recognized scientists in Research and Development. By focusing on therapeutic areas with high medical need, the company is positioned for growth and success.

Early Access Program for Pritelivir

AiCuris collaborates with myTommorrows to initiate an Early Access Program for Pritelivir
  • The Early Access Program may provide access to Pritelivir for use in immunocompromised patients that have acyclovir-resistant mucocutaneous herpes simplex virus infections
  • An Early Access Program offers a method to provide patients with an unmet medical need with possible access to medication currently not licensed in their home country

You're a patient or a doctor interested in the program? Please find more information here

Read more ...

AiCuris Provides Corporate Update

AiCuris Anti-infective Cures GmbH today provided a strategic update, outlining its recent achievements and plans for future growth.
  • Over 15,000 patients worldwide already treated with Letermovir to prevent Cytomegalovirus (CMV) infection and disease in allogeneic stem cell transplantation
  • Pritelivir in Phase 2 testing for treatment of Acyclovir resistant HSV infections in immune-comprised patients; AiCuris is preparing a pivotal Phase 3 trial
  • AIC649, a potential cure for chronic hepatitis B, to be partnered
  • Company fully dedicated to develop novel antibiotics to combat antimicrobial resistance
  • Significant ongoing revenue stream provides funding to carry out ambitious plans

Read more ...

PREVYMIS® @ Deutsches Museum

Letermovir project by AiCuris becomes part of the permanent exhibition of Deutsches Museum in Munich

The Letermovir project, which was awarded the German Future Prize 2018, will be on public display for the next ten years at the Deutsches Museum.
The winners, Prof. Dr. Helga Rübsamen-Schaeff, founding CEO, and Dr. Holger Zimmermann, CEO of AiCuris Anti-Infective Cures GmbH, unveiled the module yesterday at a festive event.

Read more ...